240 related articles for article (PubMed ID: 18802015)
1. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients.
Stroes ES; Nierman MC; Meulenberg JJ; Franssen R; Twisk J; Henny CP; Maas MM; Zwinderman AH; Ross C; Aronica E; High KA; Levi MM; Hayden MR; Kastelein JJ; Kuivenhoven JA
Arterioscler Thromb Vasc Biol; 2008 Dec; 28(12):2303-4. PubMed ID: 18802015
[No Abstract] [Full Text] [Related]
2. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation.
Ross CJ; Twisk J; Meulenberg JM; Liu G; van den Oever K; Moraal E; Hermens WT; Rip J; Kastelein JJ; Kuivenhoven JA; Hayden MR
Hum Gene Ther; 2004 Sep; 15(9):906-19. PubMed ID: 15353045
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy.
Ferreira V; Twisk J; Kwikkers K; Aronica E; Brisson D; Methot J; Petry H; Gaudet D
Hum Gene Ther; 2014 Mar; 25(3):180-8. PubMed ID: 24299335
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for lipoprotein lipase deficiency: working toward clinical application.
Rip J; Nierman MC; Sierts JA; Petersen W; Van den Oever K; Van Raalte D; Ross CJ; Hayden MR; Bakker AC; Dijkhuizen P; Hermens WT; Twisk J; Stroes E; Kastelein JJ; Kuivenhoven JA; Meulenberg JM
Hum Gene Ther; 2005 Nov; 16(11):1276-86. PubMed ID: 16259561
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for genetic lipid disorders: lipoprotein lipase deficiency as a paradigm.
Rader DJ
Neth J Med; 2005 Jan; 63(1):2-3. PubMed ID: 15719845
[No Abstract] [Full Text] [Related]
6. Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency.
Burnett JR; Hooper AJ
Curr Opin Mol Ther; 2009 Dec; 11(6):681-91. PubMed ID: 20072945
[TBL] [Abstract][Full Text] [Related]
7. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency.
Gaudet D; de Wal J; Tremblay K; Déry S; van Deventer S; Freidig A; Brisson D; Méthot J
Atheroscler Suppl; 2010 Jun; 11(1):55-60. PubMed ID: 20427244
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice.
Nierman MC; Rip J; Twisk J; Meulenberg JJ; Kastelein JJ; Stroes ES; Kuivenhoven JA
Neth J Med; 2005 Jan; 63(1):14-9. PubMed ID: 15719847
[TBL] [Abstract][Full Text] [Related]
9. Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency.
Haddley K
Drugs Today (Barc); 2013 Mar; 49(3):161-70. PubMed ID: 23527320
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy enters the pharma market: the short story of a long journey.
Büning H
EMBO Mol Med; 2013 Jan; 5(1):1-3. PubMed ID: 23283747
[No Abstract] [Full Text] [Related]
11. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients.
Carpentier AC; Frisch F; Labbé SM; Gagnon R; de Wal J; Greentree S; Petry H; Twisk J; Brisson D; Gaudet D
J Clin Endocrinol Metab; 2012 May; 97(5):1635-44. PubMed ID: 22438229
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for lipoprotein lipase deficiency.
Gaudet D; Méthot J; Kastelein J
Curr Opin Lipidol; 2012 Aug; 23(4):310-20. PubMed ID: 22691709
[TBL] [Abstract][Full Text] [Related]
13. A largely random AAV integration profile after LPLD gene therapy.
Kaeppel C; Beattie SG; Fronza R; van Logtenstein R; Salmon F; Schmidt S; Wolf S; Nowrouzi A; Glimm H; von Kalle C; Petry H; Gaudet D; Schmidt M
Nat Med; 2013 Jul; 19(7):889-91. PubMed ID: 23770691
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein lipase deficiency in an infant.
Nampoothiri S; Radhakrishnan N; Schwentek A; Hoffmann MM
Indian Pediatr; 2011 Oct; 48(10):805-6. PubMed ID: 22080683
[TBL] [Abstract][Full Text] [Related]
15. AAV1-LPL(S447X) gene therapy reduces hypertriglyceridemia in apoE2 knock in mice.
Rip J; van Dijk KW; Sierts JA; Kastelein JJ; Twisk J; Kuivenhoven JA
Biochim Biophys Acta; 2006 Oct; 1761(10):1163-8. PubMed ID: 16990047
[TBL] [Abstract][Full Text] [Related]
16. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation.
Ross CJ; Twisk J; Bakker AC; Miao F; Verbart D; Rip J; Godbey T; Dijkhuizen P; Hermens WT; Kastelein JJ; Kuivenhoven JA; Meulenberg JM; Hayden MR
Hum Gene Ther; 2006 May; 17(5):487-99. PubMed ID: 16716106
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial.
Gaudet D; Méthot J; Déry S; Brisson D; Essiembre C; Tremblay G; Tremblay K; de Wal J; Twisk J; van den Bulk N; Sier-Ferreira V; van Deventer S
Gene Ther; 2013 Apr; 20(4):361-9. PubMed ID: 22717743
[TBL] [Abstract][Full Text] [Related]
18. Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency.
Wierzbicki AS; Viljoen A
Expert Opin Biol Ther; 2013 Jan; 13(1):7-10. PubMed ID: 23126631
[TBL] [Abstract][Full Text] [Related]
19. Adeno-associated virus LPL(S447X) gene therapy in LDL receptor knockout mice.
Rip J; Sierts JA; Vaessen SF; Kastelein JJ; Twisk J; Kuivenhoven JA
Atherosclerosis; 2007 Sep; 194(1):55-61. PubMed ID: 17087965
[TBL] [Abstract][Full Text] [Related]
20. Insulin sensitivity is impaired in heterozygous carriers of lipoprotein lipase deficiency.
Hölzl B; Iglseder B; Sandhofer A; Malaimare L; Lang J; Paulweber B; Sandhofer F
Diabetologia; 2002 Mar; 45(3):378-84. PubMed ID: 11914743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
